US Patent

US12070449 — Methods of treating TTR amyloidosis using AG10

Method of Use · Assigned to Eidos Therapeutics Inc · Expires 2039-03-22 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating transthyretin (TTR) amyloidosis in a subject using AG10.

USPTO Abstract

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects

Drugs covered by this patent

acoramidis-hydrochloride (ACORAMIDIS HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4046`	—	acoramidis-hydrochloride

Patent Metadata

Patent number: US12070449
Jurisdiction: US
Classification: Method of Use
Expires: 2039-03-22
Drug substance claim: No
Drug product claim: No
Assignee: Eidos Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.